This commentary, featured by JAMA, discusses the rationale for considering cardiovascular disease prevention efforts in childhood including recommendations for universal screening for lipid levels in children at 9 to 11 years of age and again at 17 to 21 years of age.

The author debates whether screening and treating dyslipidaemia during childhood may be less effective and more hazardous.